CD22AB: A phase I, multi-center, dose escalation study of CAT-8015 in children, adolescents and young adults with refractory CD22+ acute lymphoblastic leukemia (ALL), or non-Hodgkin’s Lymphoma (NHL) (CAT-8015-1004)


    Leukemias / Lymphomas : acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), including lymphoblastic lymphoma, Burkitt’s lymphoma, and large cell lymphoma


    The main purpose of this study is to estimate the maximum tolerated dose (MTD), defined as the highest dose of CAT-8015 that can be safely administered to a patient. This information will be used to recommend the next phase dosage for further pediatric development. The drug CAT-3888, a closely related predecessor compound, has been well tolerated and highly effective in adult patients with lymphoid malignancies.

    CAT-8015 is made up of two parts: 1) a modified mouse antibody that combines with a protein from the immune system, called “CD22”, which can also be found on the surface of cancer cells, and 2) a toxin (a type of poison). In laboratory experiments, CAT-8015 has been shown to kill leukemia cells that have the CD22 protein on their surface.

    CAT-8015 will be given in "cycles" with each cycle lasting about 3 weeks. How long you stay on this study will depend on the number of treatment cycles that you receive.





    Deepa Bhojwani, MD
    St. Jude Children’s Research Hospital
    262 Danny Thomas Place
    Memphis, TN  38105  USA
    Voice: 1-866-2ST-JUDE  (1-866-278-5833)
    FAX: 901-521-9005

    Referring or consulting physicians only:
    For all other inquiries about St. Jude Children's Research Hospital studies:

    The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.